- Home
- Products
Zynlonta (Loncastuximab Tesirine-lpyl)
Zynlonta (Loncastuximab Tesirine-lpyl)
- Medicine Name: Zynlonta
- Generic Name: Loncastuximab Tesirine
- Dosage Form & Strength: Injection – 10 mg lyophilized powder for reconstitution
- Manufactured By: ADC Therapeutics SA
Zynlonta is a CD19-directed antibody-drug conjugate indicated for the treatment of adult patients with:
- Relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy
- Includes:
- Diffuse large B-cell lymphoma (DLBCL) not otherwise specified
- DLBCL arising from low-grade lymphoma
- High-grade B-cell lymphoma
Recommended Dosage:
- Administered via intravenous infusion over 30 minutes on Day 1 of each 3-week cycle
- Cycle 1–2: 0.15 mg/kg every 3 weeks
- Subsequent cycles: 0.075 mg/kg every 3 weeks
- Premedication: Start dexamethasone 4 mg (oral or IV) twice daily for 3 days, beginning the day prior to Zynlonta treatment
- Effusions and Edema: Monitor for signs of pleural effusion or generalized edema. Initiate appropriate medical treatment.
- Myelosuppression: Common adverse effects include thrombocytopenia, neutropenia, and anemia. Regularly monitor complete blood counts (CBCs).
- Infections: Serious or fatal infections may occur. Evaluate and manage new or worsening signs of infection promptly.
- Severe Cutaneous Reactions: Monitor for rash, photosensitivity, or worsening dermatologic conditions.
- Embryo-Fetal Toxicity: Zynlonta contains a genotoxic payload (SG3199) and may cause fetal harm. Contraceptive measures are recommended during treatment and for a period after final dose.
To import Zynlonta (Loncastuximab Tesirine) via GlobalRareMeds, you’ll need the following:
- A valid prescription from a qualified oncologist
- Diagnostic reports confirming relapsed/refractory large B-cell lymphoma
- Patient’s government-issued ID
Order Confirmation:
Your order will be processed only after receiving the complete documentation and, where applicable, an import permit.
GlobalRareMeds sources Zynlonta 10 mg injection from licensed and verified global distributors across USA, Canada, Europe, and Australia.
Our fulfillment center in Ambernath, Thane District, ensures cold-chain compliant delivery. We dispatch only after verification by a registered pharmacist.
We serve:
- India – Including cities such as Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Kolkata, Ahmedabad, Pune, and more
- Global locations, adhering to respective import regulations
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name of Zynlonta?
A. The generic name is Loncastuximab Tesirine.
Q. Who manufactures Zynlonta?
A. Zynlonta is manufactured by ADC Therapeutics SA.
Q. Is Zynlonta approved by the FDA?
A. Yes, Zynlonta was approved by the U.S. FDA on April 23, 2021.
Q. What is Zynlonta used for?
A. It is indicated for relapsed or refractory large B-cell lymphoma (LBCL), including DLBCL and high-grade subtypes, after ≥2 prior therapies.
Q. What dosage form is Zynlonta supplied in?
A. Zynlonta is supplied as a 10 mg lyophilized powder in a single-dose vial, reconstituted for IV infusion.
Q. What are common side effects of Zynlonta?
A. Common side effects include:
Skin rash, fatigue, swelling, nausea, muscle/joint pain, hyperglycemia, and lab abnormalities.
Q. Can Zynlonta be used during pregnancy?
A. Zynlonta may cause embryo-fetal harm. Avoid use during pregnancy and ensure effective contraception during and after therapy.
Q. How should Zynlonta be stored?
A. Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton. Do not freeze or shake.
Q. How can I buy Zynlonta in India?
A. Submit valid medical documents to GlobalRareMeds. We ensure legal, secure, and compliant access to Zynlonta across India and select international regions.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
